Skip to main content
. 2024 Jul 3;38(4):1891–1899. doi: 10.21873/invivo.13644

Table III. Treatment responses of evaluable patients.

graphic file with name in_vivo-38-1895-i0001.jpg

CI: Confidence interval; CR: complete response; ICI: immune checkpoint inhibitor; PD: progressive disease; PR: partial response; SD: stable disease; TI: paclitaxel-ifosfamide. aOne of the evaluable patients received paclitaxel-ifosfamide in combination with pembrolizumab and lenvatinib, and the best response was PD.